NovaBay Pharmaceuticals, Inc. (NBY)

NovaBay Pharmaceuticals, Inc. (NBY) Healthcare & Pipeline Overview

NovaBay Pharmaceuticals, Inc. develops and markets Avenova for eyecare and DERMAdoctor for skincare, targeting specific dermatological conditions and hygiene. With a small team, they distribute through retail, digital, and online channels, facing competition in the broader pharmaceutical and beauty sectors.

What Is the Investment Thesis for NBY?

NovaBay Pharmaceuticals, Inc. presents a high-risk, high-reward investment profile. The company's profitability, indicated by a profit margin of 21217.7%, is notable, but must be considered in the context of a negative gross margin of -3.5%. The high dividend yield of 320.00% may attract income-seeking investors, but its sustainability needs careful evaluation. Growth catalysts include expanding the market reach of Avenova and DERMAdoctor products through strategic partnerships and digital marketing. The company's small size and limited resources pose risks, particularly in competing with larger pharmaceutical and skincare companies. The low beta of 0.16 suggests lower volatility compared to the overall market.

Based on FMP financials and quantitative analysis

NBY Key Highlights

• Market capitalization of $39.14M indicates a micro-cap company with potential for high growth but also significant risk.
• P/E ratio of 0.1 suggests the company is potentially undervalued relative to its earnings.
• Profit margin of 21217.7% reflects strong profitability, but should be analyzed in the context of revenue and cost structure.
• Gross margin of -3.5% indicates that the cost of goods sold exceeds revenue, requiring further investigation into pricing and production efficiency.
• Dividend yield of 320.00% is exceptionally high, raising questions about its sustainability and the company's long-term financial health.

Who Are NBY's Competitors?

NBY is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are NBY's Key Strengths?

• Proprietary Avenova formulation with a unique mechanism of action.
• Established DERMAdoctor brand with a loyal customer base.
• Diverse distribution channels including retail, digital, and online.
• High profit margin (21217.7%) indicates strong profitability potential.

What Are NBY's Weaknesses?

• Small company size with limited resources.
• Negative gross margin (-3.5%) indicates cost inefficiencies.
• High dependence on key products like Avenova.
• Limited marketing and sales capabilities compared to larger competitors.

What Could Drive NBY Stock Higher?

• Potential FDA approval for new dermatological products under the DERMAdoctor brand.
• Expansion of Avenova's distribution network through strategic partnerships.
• Increasing brand awareness through digital marketing and social media campaigns.
• Launch of new skincare formulations targeting specific dermatological conditions.

What Are the Key Risks for NBY?

• Financial-distress signal — its Altman Z-Score of -1.47 sits in the distress zone (elevated bankruptcy risk).
• Competition from larger pharmaceutical and skincare companies with greater resources.
• Regulatory hurdles and delays in product approvals.
• Dependence on key products like Avenova for revenue generation.
• Economic downturns affecting consumer spending on discretionary skincare products.

What Are the Growth Opportunities for NBY?

• Expanding Avenova's Market Reach: Avenova's potential in addressing blepharitis and dry eye offers a significant growth opportunity. The global dry eye syndrome market is projected to reach $6.5 billion by 2028. NovaBay can capitalize on this by increasing awareness among eye care professionals and consumers through targeted marketing campaigns and strategic partnerships with optometry practices. Timeline: Ongoing, with continuous efforts to expand market penetration.
• Leveraging the DERMAdoctor Brand: The DERMAdoctor brand provides NovaBay with a platform to address a wide range of skincare concerns. The global skincare market is estimated at $145 billion. By developing and launching new products under the DERMAdoctor brand, focusing on specific niches like anti-aging or acne treatment, NovaBay can attract new customers and increase revenue. Timeline: Within the next 1-2 years, with new product launches planned.
• Strategic Partnerships and Distribution Agreements: Forming partnerships with larger pharmaceutical companies or established skincare distributors can significantly expand NovaBay's reach and market access. This can provide access to new markets and customer segments, accelerating revenue growth. Timeline: Ongoing, with active pursuit of potential partnerships.
• Enhancing Digital Marketing and E-commerce Capabilities: Investing in digital marketing and e-commerce platforms can improve NovaBay's ability to reach and engage with customers directly. This includes optimizing the company's website, social media presence, and online advertising campaigns. Timeline: Within the next 6-12 months, with planned upgrades to digital infrastructure.
• International Expansion: Expanding into international markets, particularly in Asia and Europe, represents a significant growth opportunity. These markets have a large and growing demand for skincare and eyecare products. NovaBay can enter these markets through strategic partnerships or by establishing its own distribution networks. Timeline: Within the next 2-3 years, with initial focus on select markets.

What Opportunities Does NBY Have?

• Expanding Avenova's market reach through strategic partnerships.
• Developing new products under the DERMAdoctor brand to address unmet needs.
• Entering new geographic markets with high growth potential.
• Leveraging digital marketing and e-commerce to reach a wider audience.

What Threats Does NBY Face?

• Competition from larger pharmaceutical and skincare companies.
• Regulatory hurdles and potential delays in product approvals.
• Risk of product obsolescence due to technological advancements.
• Economic downturns affecting consumer spending on discretionary skincare products.

What Are NBY's Competitive Advantages?

• Proprietary Avenova formulation provides a differentiated solution for eye hygiene.
• Established DERMAdoctor brand recognition in the dermatological skincare market.
• Distribution network through retailers, digital channels, and online platforms.
• Focus on specific niche markets within the broader eyecare and skincare industries.

What Does NBY Do?

NovaBay Pharmaceuticals, Inc., established in 2000 and headquartered in Emeryville, California, is a pharmaceutical company focused on the development and commercialization of innovative anti-infective products. Originally named NovaCal Pharmaceuticals, Inc., the company rebranded in 2007 to reflect its evolving focus. NovaBay's primary product, Avenova, is a proprietary, pure hypochlorous acid solution used for cleansing the eyelids and lashes, targeting conditions like blepharitis and dry eye. Avenova is designed to remove microorganisms and debris, promoting ocular health. In addition to Avenova, NovaBay offers wound care products under the NeutroPhase and PhaseOne brands. These products are designed to aid in wound healing and prevent infection. Furthermore, NovaBay has expanded its portfolio through the DERMAdoctor brand, providing a range of dermatological solutions for skincare concerns such as keratosis pilaris, rosacea, eczema, anti-aging, SPF protection, hyperhidrosis, excessive hair, and acne. The company distributes its products through a variety of channels, including retailers, digital beauty platforms, distributors, and its own online store, reaching both domestic and international markets. NovaBay operates with a relatively small team of 13 employees, indicating a lean operational structure.

What Products and Services Does NBY Offer?

• Develop and sell Avenova, a solution for removing microorganisms and debris from the skin around the eye.
• Offer wound care products under the NeutroPhase and PhaseOne brands.
• Provide dermatological solutions under the DERMAdoctor brand for skincare concerns like keratosis pilaris, rosacea, and acne.
• Distribute products through retailers, digital beauty channels, and distributors.
• Sell products online through their own e-commerce platform.
• Focus on addressing specific skincare concerns with targeted solutions.

How Does NBY Make Money?

• Develop and manufacture eyecare and skincare products.
• Market and sell products directly to consumers through online channels.
• Distribute products through retail partners and distributors.
• Generate revenue through product sales.

What Industry Does NBY Operate In?

NovaBay Pharmaceuticals, Inc. operates within the competitive biotechnology and skincare industries. The biotechnology sector is characterized by high research and development costs, regulatory hurdles, and intense competition. The skincare market is driven by consumer demand for innovative and effective products addressing various dermatological concerns. NovaBay's success depends on its ability to differentiate its products, navigate regulatory pathways, and establish strong distribution channels. The company competes with both large pharmaceutical companies and smaller, specialized skincare brands. Market trends include a growing emphasis on preventative skincare and the increasing importance of digital marketing and e-commerce.

Who Are NBY's Key Customers?

• Individuals seeking solutions for eye hygiene and related conditions like blepharitis.
• Consumers looking for dermatological solutions for skincare concerns such as rosacea and eczema.
• Healthcare professionals recommending or selling NovaBay's products to their patients.
• Retailers and distributors carrying NovaBay's products.

Net buyingInsider Activity

The most recent 12 insider filings for NovaBay Pharmaceuticals, Inc. break down as 1 sales and 11 purchases. On net that is roughly 185.6M shares acquired (about $81K) — insiders putting money in tends to read as conviction.

P/E 0.1Key Financial Metrics

NBY trades at a trailing price-to-earnings ratio of 0.05, below the Healthcare sector average of ~23x. Its free cash flow yield is -31.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 5.29 indicates the company holds enough short-term assets to cover its near-term obligations.

F-Score 4/9Financial Health

NovaBay Pharmaceuticals, Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -1.47 places it in the distress zone, a signal of elevated financial risk.

FY2026 estForward Outlook

Wall Street analysts project NovaBay Pharmaceuticals, Inc. revenue of about $15.8M for fiscal 2026, with EPS near $-1.90.

NBY Valuation & Market Position

With a $39.14M market cap, NovaBay Pharmaceuticals, Inc. sits in the micro-cap segment of the market. Relative to its peer group, NBY's quantitative score of 45/100 is below the peer average of 71/100.

NBY Financials

NBY Latest News

No recent news available for NBY.

NBY Analyst Consensus

NBY MoonshotScore

NovaBay Pharmaceuticals, Inc. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources